ORMP - Oramed Pharmaceuticals Inc logo

Oramed Pharmaceuticals Inc

ORMP
Net 423xtop 1%20Y
Compare ORMP Hold

Oramed Pharmaceuticals Inc. develops oral delivery solutions for therapeutic proteins, including ORMD-0801, an oral insulin capsule in phase III trials for diabetes. The company also partners with Oravax Medical for COVID-19 oral vaccine commercialization.

βš•οΈ Healthcare NASDAQ Listed 2006 $ USD
$1,000 invested 20 years ago β†’$74,638today

Score Overview

1 Year
Score
Net Growth173.02%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score5.5
Net Growth9x
Net Trend60%
Net Income Consistencyβ€”
Rev Growth-100.00%
Rev Trend20%
Revenue Consistencyβ€”
10 Years
Score
Net Growth17x
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev Trend40%
Revenue Consistency
20 Years
Scoreβ€”
Net Growth423x
Net Trend40%
Net Income Consistency
Rev Growthβ€”
Rev Trend36%
Revenue Consistency
All Time
Scoreβ€”
Net Growth423x
Net Trend40%
Net Income Consistency
Rev Growthβ€”
Rev Trend36%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Oramed Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by Net Income Growth.

Has not reached the top 50 on Net Income Growth in any year we have ranked.

  • ORMP

2017: 98.9% Β· 2021: 86.4% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 4.12β€”
1 Year2025-10-22
$ 2.1392.98%
5 Years2021-10-22
$ 21.08-80.45%
10 Years2016-10-21
$ 6.44-36.04%
20 Years2006-10-20
$ 0.0674x
All Time2006-04-21
$ 0.0853x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00$ 174M$ 16M
2025$ 2M$ 64M$ 125M
2024$ 0.00-$ 19M$ 141M
2023$ 1M$ 5M$ 162M
2022$ 2M-$ 37M$ 155M
2021$ 2M-$ 22M$ 94M
2020$ 2M-$ 11M$ 39M
2019$ 2M-$ 14M$ 32M
2018$ 2M-$ 12M$ 30M
2017$ 2M-$ 10M$ 20M
2016$ 641K-$ 10M$ 31M
2015-$ 7M$ 17M
2014-$ 5M$ 21M
2013-$ 4M$ 8M
2012$ 184.25K-$ 3M$ 4M
2011$ 197.41K-$ 1M$ 1M
2010-$ 2M$ 1M
2009-$ 2M$ 2M
2008-$ 2M$ 4M
2007-$ 3M$ 1M
IPO2006-$ 414.58K$ 176.19K
ORMP - Oramed Pharmaceuticals Inc logo

Oramed Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 2M to $ 2M and net income went from -$ 11M to $ 64M. Revenue increased in 1 of those 5 years; net income in 3.

Between 2015 and 2025, net income went from -$ 7M to $ 64M. Revenue increased in 4 of those 10 years; net income in 5.

Oramed Pharmaceuticals Inc currently holds a 5-year HDB Score of 5.5 out of 10. How the HDB Score is calculated.

Membership

Continue ORMP’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies